Gkika Eleni
@gkikaeleni2
ID: 1115363699701817344
08-04-2019 21:20:03
124 Tweet
117 Takipçi
221 Takip Edilen
Check out our newest paper on risk factors for BCR after PSMA-guided RT in de novo lymph node positive #prostatecancer in Frontiers - Oncology! 👉🏼 > 2 nodes associated with worse bRFS 👉🏼 high SUVmax associated with worse MFS #radonc Constantinos Zamboglou Uniklinik Freiburg doi.org/10.3389/fonc.2…
A new report from Shankar Siva shows why TOTAL METASTATIC ABLATION is preferred whenever feasible. #radonc 1/
1/ I wonder why we find the key quality indicators in Checkmate 816 of “surgical outcomes” on pg36 of the supplement T5? Importantly, 30-day mortality and rate of R0 resection seem worse than 6 other neoadjuvant studies. #radonc #tssmn The Society of Thoracic Surgeons CTSurgSocMedNetwork
2/ elegantly query by Chris Cao in letter to editor - bit.ly/3BTV1ZK. We need to be carefully selecting patients for neoadj. ChemoIO if it risks early death or needing PORT Jonathan Spicer MD PhD Patrick Forde H. Jack West, MD, FASCO Sanjay Popat Drew Moghanaki 🐕 Brendon Stiles
Presented at #ESMO22 ESMO - Eur. Oncology, now in our Oct issue: interim analysis of PEARLS/KEYNOTE-091: #pembrolizumab vs placebo as #adjuvant therapy for completely resected stage IB–IIIA non-small-cell #lungcancer #NSCLC thelancet.com/journals/lanon…
Check out our paper in IJROBP - The Red Journal on genomic classifiers in personalized RT of #prostatecancer. We conducted a systematic review and delphi consensus with experts across the world! Focusing on the setting of RT this paper is for the #radonc and #GU cancer community
Check out the latest paper by Gkika Eleni Elke Firat Simon Lo NilsNicolay Dan Duda Anca-L. Grosu, MD Great collaboration with Edwin L. Steele Laboratories on the first results of the LAPIS trial published in npj Journals precision oncology. nature.com/articles/s4169… #lungcancer